These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37303270)

  • 1. An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.
    Oni-Orisan A; Tuteja S; Hoffecker G; Smith DM; Castrichini M; Crews KR; Murphy WA; Nguyen NHK; Huang Y; Lteif C; Friede KA; Tantisira K; Aminkeng F; Voora D; Cavallari LH; Whirl-Carrillo M; Duarte JD; Luzum JA;
    Clin Pharmacol Ther; 2023 Aug; 114(2):275-287. PubMed ID: 37303270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.
    Joseph PG; Pare G; Ross S; Roberts R; Anand SS
    Clin Cardiol; 2014 Jan; 37(1):48-56. PubMed ID: 24105892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics to guide cardiovascular drug therapy.
    Duarte JD; Cavallari LH
    Nat Rev Cardiol; 2021 Sep; 18(9):649-665. PubMed ID: 33953382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.
    Sleder AT; Kalus J; Lanfear DE
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):20-6. PubMed ID: 26054891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease.
    Friede K; Li J; Voora D
    Clin Chem; 2017 Jan; 63(1):177-185. PubMed ID: 27864383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine.
    Dávila-Fajardo CL; Díaz-Villamarín X; Antúnez-Rodríguez A; Fernández-Gómez AE; García-Navas P; Martínez-González LJ; Dávila-Fajardo JA; Barrera JC
    Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30939847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics in cardiovascular diseases: State of the art and implementation-recommendations of the French National Network of Pharmacogenetics (RNPGx).
    Lamoureux F; Duflot T;
    Therapie; 2017 Apr; 72(2):257-267. PubMed ID: 28237404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of chronic cardiovascular drugs: applications and implications.
    Zineh I; Johnson JA
    Expert Opin Pharmacother; 2006 Aug; 7(11):1417-27. PubMed ID: 16859425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.
    Shahabi P; Dubé MP
    Int J Cardiol; 2015 Apr; 184():772-795. PubMed ID: 25838112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
    Johnson JA; Cavallari LH
    Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A qualitative systematic review of internal and external influences on shared decision-making in all health care settings.
    Truglio-Londrigan M; Slyer JT; Singleton JK; Worral P
    JBI Libr Syst Rev; 2012; 10(58):4633-4646. PubMed ID: 27820528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
    Zhang Z; Wu Y; Tan NC; Jiang Y
    Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of physician opinions in Russia in the field of pharmacogenetics of cardiovascular disease.
    Sychev D; Fedina L; Poptsova M; Zateyshchikov D; Mirzaev K; Tsimbal E; Sychev I; Rastvorova T
    Pharmacogenomics; 2022 Oct; 23(15):847-856. PubMed ID: 36093937
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenetics in Cardiovascular Medicine.
    Weeke PE
    Adv Pharmacol; 2018; 83():333-360. PubMed ID: 29801582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHARMACOGENOMIC DETERMINANTS OF RESPONSE TO CARDIOVASCULAR DRUGS.
    Stankov KM; Stanimirov BG; Mikov MM
    Med Pregl; 2015; 68(7-8):259-65. PubMed ID: 26591639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management.
    Humma LM; Terra SG
    Am J Health Syst Pharm; 2002 Jul; 59(13):1241-52. PubMed ID: 12116890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.